Table 1.

Technical summary of current COVID-19 vaccines

	Vaccine name
	BNT162b2	mRNA-1273	AZD1222	Ad26.COV2.S
Manufacturer	Pfizer-BioNTech	Moderna	AstraZeneca	Johnson & Johnson/Janssen
Platform	mRNA	mRNA	Viral vector (recombinant adenovirus, ChAdOx1)	Viral vector (human adenovirus serotype 26, Ad26)
No. of doses (schedule) Phase 3 KDCA guidance	2-dose (21 d) 2-dose (21 d)	2-dose (28 d)	2-dose (28 d) 2-dose (8 to 12 wk)	1-dose
Route	Intramuscular	Intramuscular	Intramuscular	Intramuscular
Approved age (y)	≥16	≥18	≥18	≥18
Cost per dose US EU	$19.50 $14.76	$15.00 $18.00	$4.00 $2.19	$10.00 $8.50
Administration conditions	2 to 25°C (6 hr)	Room temperature (6 hr)	2 to 8°C (48 hr)	Refrigerated (4 to 6 hr)
Transport conditions	2 to 8°C (5 d) −25 to−15°C(2 wk)	2 to 8°C (30 d)	2 to 8°C (6 mon)	2 to 8°C (3 mon)
Storage conditions	−80 to −60°C (6 mon)	−20°C (6 mon)	2 to 8°C (6 mon)	−25 to −15°C (24 mon)
Early, limited, or emergency use (as of March 26, 2021)*	Australia, Canada, EU, Iceland, Israel, Japan, South Korea, Switzerland, United Kingdom, US FDA, WHO, etc. (≥41 countries)	Canada, EU, Iceland, Israel, Switzerland, United Kingdom, US FDA, WHO, etc. (≥12 countries)	Australia, Canada, EU, Iceland, India, South Korea, United Kingdom, WHO, etc. (≥49 countries)	Canada, EU, Iceland, Switzerland, US FDA, WHO (≥8 countries)

Abbreviations: EU, European Union; KDCA, Korea Disease Control and Prevention Agency; US FDA, United States Food and Drug Administration.

*Alphabetical order.